Selected Articles from This Issue

Highlights| May 15 2024 Selected Articles from This Issue Author 30 (10): 2003. https://doi.org/10.1158/1078-0432.CCR-30-10-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Although KRAS mutations are common in patients with colorectal cancer, efforts to target KRAS have had limited success, necessitating the development of additional treatment options. In patients with metastatic colorectal cancer (mCRC) who progress after first-line treatment, further therapy with FOLFIRI and the VEGF-targeting bevacizumab has had modest efficacy. Polo-like kinase 1 (PLK1) levels were found to be increased in relapsed colorectal tumors, suggesting it may contribute to resistance. In a phase Ib clinical study, Ahn and colleagues preclinically and clinically evaluated the PLK inhibitor onvansertib with chemotherapy for treating KRAS-mutant mCRC. Preclinically, the authors demonstrate increased onvansertib activity in KRAS-mutant in vitro models and significant antitumor activity when combined with chemotherapy in vivo. In patients with mCRC, the authors observed partial responses in 44% of patients treated with onvansertib plus FOLFIRI/bevacizumab, with a tolerable safety profile. Early changes in KRAS-mutant circulating tumor DNA levels in... You do not currently have access to this content.